Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hims & Hers Health, Inc.HIMS · Entity 1878 | Director | August 14, 2026 | August 18, 2026 |
| INTERNATIONAL FLAVORS & FRAGRANCES INCIFF · Entity 3234 | Director | May 04, 2022 | May 06, 2022 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director · President and CEO | November 01, 2022 | November 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hims & Hers Health, Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,020 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Exercise / conversion · Acquired 6,623 · Balance 26,020 F1: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 6,624 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Exercise / conversion · Disposed 6,623 · Balance 6,624 F1: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. F2: Subject to continuous service, the RSUs under the award will vest in three substantially equal installments, with one-third of the RSUs vesting on the first Company quarterly vesting date to occur after each of the first, second, and third anniversaries of the director's service commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU.
F2: Subject to continuous service, the RSUs under the award will vest in three substantially equal installments, with one-third of the RSUs vesting on the first Company quarterly vesting date to occur after each of the first, second, and third anniversaries of the director's service commencement date.
INTERNATIONAL FLAVORS & FRAGRANCES INC
Report date May 04, 2022 · Filed May 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,344 |
Reported balance
After 2022-05-05 transaction · row 1
1 source rowRow 1 · 2022-05-05 · Exercise / conversion · Acquired 1,089 · Balance 1,344 F1: Upon the vesting of Restricted Stock Units ("RSUs") on May 5, 2022, the reporting person did not defer the receipt of 1,089 shares of Common Stock pursuant to IFF's deferred compensation plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2023-05-04 | Direct | 1,245 |
Reported balance
After 2022-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-04 · Grant · Acquired 1,245 · Balance 1,245 F2: The RSUs convert to Common Stock on a one-for-one basis. F3: Represent RSUs granted under the Non-Employee Director Compensation Program. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-05-05 | Direct | 0 |
Reported balance
After 2022-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-05 · Exercise / conversion · Disposed 1,089 · Balance 0 F2: The RSUs convert to Common Stock on a one-for-one basis. F1: Upon the vesting of Restricted Stock Units ("RSUs") on May 5, 2022, the reporting person did not defer the receipt of 1,089 shares of Common Stock pursuant to IFF's deferred compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the vesting of Restricted Stock Units ("RSUs") on May 5, 2022, the reporting person did not defer the receipt of 1,089 shares of Common Stock pursuant to IFF's deferred compensation plan.
F2: The RSUs convert to Common Stock on a one-for-one basis.
F3: Represent RSUs granted under the Non-Employee Director Compensation Program.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date November 01, 2022 · Filed November 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,542,471 |
Reported balance
After 2022-11-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-01 · Exercise / conversion · Acquired 116,389 · Balance 1,542,471 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Exercise / conversion · Disposed 116,389 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 21:04 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 6,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-26-000214 · wk-form4_1787087073.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,624 Underlying: Class A Common Stock · 6,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. F2 · derivative.exercise_date: Subject to continuous service, the RSUs under the award will vest in three substantially equal installments, with one-third of the RSUs vesting on the first Company quarterly vesting date to occur after each of the first, second, and third anniversaries of the director's service commencement date. F2 · derivative.expiration_date: Subject to continuous service, the RSUs under the award will vest in three substantially equal installments, with one-third of the RSUs vesting on the first Company quarterly vesting date to occur after each of the first, second, and third anniversaries of the director's service commencement date. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:04 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 6,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-26-000214 · wk-form4_1787087073.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:16 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 8,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-26-000192 · wk-form4_1786738568.xml · derivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,223 Underlying: Class A Common Stock · 8,223 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F2 · derivative.exercise_date: Subject to continuous service, the RSUs will vest in full on the first Company quarterly vesting date to occur after the earlier of (x) the date of the Company's next-occurring annual stockholder meeting or (y) the first anniversary of the grant date of the award. F2 · derivative.expiration_date: Subject to continuous service, the RSUs will vest in full on the first Company quarterly vesting date to occur after the earlier of (x) the date of the Company's next-occurring annual stockholder meeting or (y) the first anniversary of the grant date of the award. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:13 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 3,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-26-000115 · wk-form4_1781558016.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. F1 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. F1 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:13 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 3,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-26-000115 · wk-form4_1781558016.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 23:24 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 6,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-25-000299 · wk-form4_1758151469.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,247 Underlying: Class A Common Stock · 6,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on September 15, 2025, (ii) 1/3 of the RSUs vesting on September 15, 2026, and (iii) 1/3 of the RSUs vesting on September 15, 2027. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on September 15, 2025, (ii) 1/3 of the RSUs vesting on September 15, 2026, and (iii) 1/3 of the RSUs vesting on September 15, 2027. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 23:24 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 6,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-25-000299 · wk-form4_1758151469.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:19 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 3,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-25-000264 · wk-form4_1754684359.xml · derivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,656 Underlying: Class A Common Stock · 3,656 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. F1 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. F1 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:38 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 9,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-25-000201 · wk-form4_1750120687.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,118 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. F1 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. F1 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:38 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 9,118 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-25-000201 · wk-form4_1750120687.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:25 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 9,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-24-000270 · wk-form4_1723148701.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,118 Underlying: Class A Common Stock · 9,118 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. F3 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. F3 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:25 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 19,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-24-000270 · wk-form4_1723148701.xml · derivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,870 Underlying: Class A Common Stock · 19,870 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on September 15, 2025, (ii) 1/3 of the RSUs vesting on September 15, 2026, and (iii) 1/3 of the RSUs vesting on September 15, 2027. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on September 15, 2025, (ii) 1/3 of the RSUs vesting on September 15, 2026, and (iii) 1/3 of the RSUs vesting on September 15, 2027. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 12:55 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 116,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055177 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 116,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022. F3 · derivative.expiration_date: Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 12:55 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 116,389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-055177 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,542,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:04 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionRestricted Stock Units · Derivative | 1,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006660 · doc4.xml · derivative · entry 3 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,089 shares Expires 2022-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs convert to Common Stock on a one-for-one basis. F1 · price: Upon the vesting of Restricted Stock Units ("RSUs") on May 5, 2022, the reporting person did not defer the receipt of 1,089 shares of Common Stock pursuant to IFF's deferred compensation plan. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:04 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionCommon Stock | 1,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006660 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the vesting of Restricted Stock Units ("RSUs") on May 5, 2022, the reporting person did not defer the receipt of 1,089 shares of Common Stock pursuant to IFF's deferred compensation plan. Read SEC document |
| May 04, 2022 Filed May 6, 2022 22:04 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 1,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006660 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,245 Underlying: Common Stock · 1,245 shares Expires 2023-05-04 F2 · derivative.exercise_price: The RSUs convert to Common Stock on a one-for-one basis. F3 · shares: Represent RSUs granted under the Non-Employee Director Compensation Program. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 71,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017058 · doc4.xml · derivative · entry 7 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,879 Underlying: Ordinary Shares · 71,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 71,292 having vested on March 5, 2022, 71,292 vesting on each of March 5, 2023 and March 5, 2024, and 71,295 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 71,292 having vested on March 5, 2022, 71,292 vesting on each of March 5, 2023 and March 5, 2024, and 71,295 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 71,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017058 · doc4.xml · nonDerivative · entry 3 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 402,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017058 · doc4.xml · derivative · entry 6 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,144 Underlying: Ordinary Shares · 402,144 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 100,536 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 100,536 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 162,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017058 · doc4.xml · derivative · entry 5 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 162,593 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F4 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 59,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017058 · doc4.xml · derivative · entry 4 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,702 Underlying: Ordinary Shares · 59,701 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 59,701 having vested on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 59,701 having vested on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 162,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017058 · doc4.xml · nonDerivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 59,701 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017058 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,192,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:51 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 65,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014473 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,096 Underlying: Ordinary Shares · 65,047 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 65,047 having vested on each of February 28, 2021 and February 28, 2022, 65,047 vesting on February 28, 2023 and 65,049 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 65,047 having vested on each of February 28, 2021 and February 28, 2022, 65,047 vesting on February 28, 2023 and 65,049 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:51 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 65,047 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014473 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,132,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 26,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008417 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 26,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 26,867 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. F3 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 26,867 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 26,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-008417 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 162,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008417 · doc4.xml · derivative · entry 3 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,593 Underlying: Ordinary Shares · 162,593 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F4 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 11:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 180,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062591 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,389 Underlying: Ordinary Shares · 180,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on November 3, 2017, with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vesting on November 1, 2022. F3 · derivative.expiration_date: Restricted share units were granted on November 3, 2017, with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vesting on November 1, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 11:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 180,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-062591 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 06, 2021 Filed May 8, 2021 01:45 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionRestricted Stock Units · Derivative | 255 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007798 · doc4.xml · derivative · entry 3 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 255 shares Expires 2021-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs convert to Common Stock on a one-for-one basis. F1 · price: Upon the vesting of Restricted Stock Units ("RSUs") on May 6, 2021, the reporting person did not defer the receipt of 255 shares of Common Stock pursuant to IFF's deferred compensation plan. Read SEC document |
| May 06, 2021 Filed May 8, 2021 01:45 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionCommon Stock | 255 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007798 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the vesting of Restricted Stock Units ("RSUs") on May 6, 2021, the reporting person did not defer the receipt of 255 shares of Common Stock pursuant to IFF's deferred compensation plan. Read SEC document |
| May 05, 2021 Filed May 8, 2021 01:45 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 1,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007798 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,089 Underlying: Common Stock · 1,089 shares Expires 2022-05-05 F2 · derivative.exercise_price: The RSUs convert to Common Stock on a one-for-one basis. F3 · shares: Represent RSUs granted under the Non-Employee Director Compensation Program. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 285,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018530 · doc4.xml · derivative · entry 3 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,171 Underlying: Ordinary Shares · 285,171 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 71,292 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 71,295 vesting on March 5, 2025. F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 71,292 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 71,295 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 59,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018530 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,403 Underlying: Ordinary Shares · 59,701 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 59,701 vesting on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 59,701 vesting on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 59,701 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-018530 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:09 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 255 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004532 · doc4.xml · derivative · entry 1 Schultz Kare · CIK 0001724567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255 Underlying: Common Stock · 255 shares Expires 2021-05-06 F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2 · shares: Represent RSUs granted under the Non-Employee Director Compensation Program. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 65,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015858 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,143 Underlying: Ordinary Shares · 65,047 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 65,047 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 65,049 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 65,047 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 65,049 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 65,047 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-015858 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 26,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009645 · doc4.xml · derivative · entry 3 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,867 Underlying: Ordinary Shares · 26,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 26,867 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 26,867 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 226,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009645 · doc4.xml · nonDerivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,834 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units. F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 26,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009645 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 12:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 212,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056506 · doc4.xml · derivative · entry 4 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 212,314 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on November 3, 2020. F4 · derivative.expiration_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on November 3, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 12:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 212,314 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056506 · doc4.xml · nonDerivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 12:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 180,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056506 · doc4.xml · derivative · entry 3 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,389 Underlying: Ordinary Shares · 180,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on November 3, 2017, with 63,613 vesting on November 3, 2019, 180,000 vesting on each of November 1,2020 and November 1, 2021 and 116,389 vesting on November 1, 2022. F3 · derivative.expiration_date: Restricted share units were granted on November 3, 2017, with 63,613 vesting on November 3, 2019, 180,000 vesting on each of November 1,2020 and November 1, 2021 and 116,389 vesting on November 1, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 12:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 180,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056506 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 12:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 260,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014855 · doc4.xml · derivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,190 Underlying: Ordinary Shares · 260,190 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 65,047 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 65,049 vesting on February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 65,047 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 65,049 vesting on February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 12:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 212,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009051 · doc4.xml · derivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,314 Underlying: Ordinary Shares · 212,314 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted shares units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on November 3, 2020. F2 · derivative.expiration_date: Represents restricted shares units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on November 3, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 26,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008168 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,734 Underlying: Ordinary Shares · 26,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 26,867 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F3 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 26,867 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.